Dexmedetomidine is a medication used in this trial as a sedative for older patients who are critically ill and require ventilation. It is being tested to see if it can improve survival rates when used early as the main sedative. The trial aims to verify previous findings that suggested benefits of using dexmedetomidine in similar situations.

Acute Respiratory Distress Syndrome (ARDS) – This condition occurs when fluid builds up in the tiny, elastic air sacs in the lungs, preventing them from filling with enough air. As a result, less oxygen reaches the bloodstream, depriving organs of the oxygen they need to function. ARDS typically develops in people who are already critically ill or have significant injuries. It progresses rapidly, often within a few hours to days after the initial injury or illness. Patients may experience severe shortness of breath, labored and unusually rapid breathing, and low blood pressure. Mechanical ventilation is often required to support breathing.

Acute Kidney Injury (AKI) – This condition involves a sudden episode of kidney failure or damage that happens within a few hours or days. It causes a build-up of waste products in the blood and makes it hard for the kidneys to maintain the right balance of fluid in the body. AKI can occur due to various reasons, including reduced blood flow to the kidneys, direct damage to the kidneys, or blockage of the urinary tract. The progression can lead to symptoms such as decreased urine output, swelling due to fluid retention, and fatigue. It is often seen in critically ill patients and can be reversible with appropriate care.